Print

Adnavance Technologies Inc. to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference  
10/8/2009 11:32:45 AM

SAN DIEGO, Oct. 8 /PRNewswire/ -- Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announced today that Randy White, Ph.D. chief executive officer, will present initial data supporting direct detection of DNA targets in human clinical samples during company presentations at the following conferences:

"The hallmark of Adnavance's direct detection technology is its simplicity; it doesn't require PCR, light detection, or sample pre-treatment. We are highly encouraged by our initial data supporting the utility of our technology and its potential for use in medium complexity laboratories," said Dr. White. "Our mission is to de-centralize molecular diagnostics."

About Adnavance Technologies Inc.

Adnavance is a molecular diagnostic company focused on development of its proprietary technology that allows direct-detection of DNA targets in human clinical samples. The Company is located in San Diego, CA. The Company's patented technology is based on the change in surface charge on a gold electrode when DNA targets hybridize with capture probes anchored to the electrode surface. The Company uses a microarray of electrodes in an electrochemical cell to detect the target DNA and the inherent ultra-sensitivity of electrochemical measurements obviates the need for target amplification used in current molecular-based tests. In addition, the electrochemical measurement simplifies the medical device and eliminates sample pre-treatment steps required for PCR-based tests. Adnavance scientists were the first to discover the surface charge phenomenon, and the Company believes its technology platform will open new molecular testing markets. For additional information please see the Company website at www.adnavance.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate," and similar words indicating uncertainty in facts and figures. Although Adnavance believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with the technology development process, the risk that Adnavance technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing to commercialize the technology platform.

SOURCE Adnavance Technologies Inc.

CONTACT: Media, Kim Richards of Porter Novelli Life Sciences,
+1-619-849-5377, krichards@pnlifesciences.com

Web site: http://www.adnavance.com/


//-->